Election Day Approaches: Stocks Poised for Growth
As the highly anticipated 2024 elections draw near, the stock market remains robust, with the S&P 500 surging 20% year-to-date. Historically, election years have been kind to the index, but this year’s performance has been exceptional, making it the most bullish election-year market in decades.
A Perfect Storm of Macro Factors
A mix of macroeconomic factors, particularly expectations of further Fed rate cuts, has fueled strong investor confidence. This optimism has led Morgan Stanley’s analysts to identify two stocks that are primed for substantial growth, regardless of the election outcome. Both stocks boast a unanimous Strong Buy consensus rating from analysts.
Tenaya Therapeutics: A Heart-Focused Biotech
Tenaya Therapeutics, a research-oriented biopharmaceutical company, is developing novel therapeutic drugs to treat heart disease, the world’s leading cause of death among adults. The company’s approach includes gene therapies, cellular regeneration, and precision medicines. Two primary drug candidates, TN-201 and TN-401, are currently under investigation.
Morgan Stanley analyst Michael Ulz views Tenaya as a compelling investment, with TN-201 as the primary value driver. Ulz expects interim Phase 1b data for TN-201 to be released in December, representing a key catalyst for the stock. He predicts a potential upside of 670% from current levels, with a $15 price target.
Royalty Pharma: A Unique Biotech Play
Royalty Pharma operates as a royalty company, purchasing ownership rights in biopharmaceutical products and earning royalties on sales and profits. The company has built a solid portfolio of assets, boasting rights in over 35 approved products and 17 drug candidates still in development.
Morgan Stanley analyst Terence Flynn takes an upbeat view of Royalty Pharma, citing its high top-line growth rate and diversified portfolio. Flynn expects the company to continue deploying capital towards new deals, sustaining high single-digit growth. He predicts a potential one-year upside of 88%, with a $51 price target.
A Consensus of Confidence
Both Tenaya Therapeutics and Royalty Pharma enjoy unanimous support from analysts, with Strong Buy consensus ratings. As the election approaches, these stocks are poised for growth, regardless of the outcome.
Leave a Reply